Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium : an observational study

Objective : To describe comorbidities and concomitant medications in patients initiating treatment for hepatitis C virus (HCV) infection with direct-acting antiviral (DAA) regimens in Belgium. Methods : This was a noninterventional, observational, multi-center study of data from patient charts. Adult patients with HCV infection receiving second-generation DAA therapy were included. Comorbidities were assessed at the time of HCV treatment initiation. Concomitant medications were recorded at the time of diagnosis and at treatment initiation. Potential clinically relevant drug-drug interactions (... Mehr ...

Verfasser: Bourgeois, S.
Mulkay, J. P.
Cool, M.
Verhelst, X.
ROBAEYS, Geert
Lasser, L.
Lefebvre, V
Colle, I
Van Steenkiste, C.
Decaestecker, J.
Coulon, S.
VENKEN, Koen
Vanwolleghem, T.
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Verlag/Hrsg.: UNIV CATHOLIQUE LOUVAIN-UCL
Schlagwörter: hepatitis C / drug-drug interactions / direct-acting antivirals / Belgium / co-medication
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28928310
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/1942/33924